Business
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
New US patent 12,496,345 strengthens the existing portfolioPatents now granted in 41 countries protect the Company's novel intratumoral technology, including
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"New US patent 12,496,345 strengthens the existing portfolioPatents now granted in 41 countries protect the Company's novel intratumoral technology, including lead compound INT230-6SHELTON, Conn., March 24, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) (\"Intensity\" or the \"Company\"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, provided an update on its patent portfolio including the recent issuance in December 2025 of a new US patent in the U.S., US Patent Number 12,496,345, entitled \"A Method of Treating Cancer\".\n \n \n \n \n \n \n \nLewis H. Bender, Founder, President & CEO, said, \"The issuance of this new patent supports the novelty of our unique technology in the U.S. and around the world. The Company now has four U.S. patents and one pending U.S. patent application. We have protection in 41 countries, including our European patent, which is validated in 27 countries. We have registered trademarks, know-how, and continue to generate additional potential new intellectual property.\" About Intensity Therapeutics Intellectual Property PortfolioThe Company has a robust intellectual property position with 19 issued patents (with four of such patents being issued in the U.S.). We have the ability to enforce our patent claims in 41 countries, including the U.S. and all external major pharmaceutical markets. The four United States Patent and Trademark Office (\"PTO\") issued patents are as follows; (i) US Patent Number 9,351,997 is directed to a method of treating cancer, with a registration date of May 31, 2016 and an expiration date of December 6, 2033, (ii) US Patent Number 9,636,406 is directed to a method of treating cancer, with a registration date of May 2, 2017 and an expiration date of September 15, 2033, (iii) US Patent Number 10,888,618 is directed to a method of treating cancer, with a registration date of January 12, 2021 and an expiration date of September 15, 2033, and (iv) new US Patent Number 12,496,345 is directed to a method of treating cancer and an intratumoral formulation, with a registration date of December 16, 2025 and an expiration date of September 15, 2033...